This article was originally published in The Gray Sheet
Executive SummaryDiagnostics developer raises $30 mil. from Swartz Private Equity, LLC, to be drawn by Lexon as needed over the next three years. Tulsa, Oklahoma-based Lexon, which owns the exclusive worldwide rights to the Ebaf Assay blood test to screen for colon cancer and the Telomerase Assay blood test to screen for lung cancer, will use the funds for "ongoing product development and initiation of FDA clinical trials," the firm states in an Aug. 21 release. Current development efforts "are focused on expanding the battery of monoclonal antibodies for each test, producing prototype blood screening test kits, performing multiple blood tests on known cancer patients, and statistically evaluating test results for presentation to the FDA," Lexon reports
You may also be interested in...
The December 12 UK general election returned a Conservative majority, the scale or which few would have predicted. It means that the new government can press on with its plans for Brexit, the uncertainty now surrounding only when, not if.
A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.